Frederick Howard to Triple Negative Breast Neoplasms
This is a "connection" page, showing publications Frederick Howard has written about Triple Negative Breast Neoplasms.
Connection Strength
3.758
-
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Netw Open. 2025 Feb 03; 8(2):e2460243.
Score: 0.758
-
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
Score: 0.667
-
Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Aug; 195(1):1-15.
Score: 0.635
-
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs. 2022 Jun; 31(6):531-548.
Score: 0.603
-
Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J. 2021 Jan-Feb 01; 27(1):8-16.
Score: 0.571
-
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
Score: 0.190
-
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
Score: 0.169
-
Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
Score: 0.166